Z variant heterozygosity in alpha-1 antitrypsin deficiency: disease risk and treatment implications

By afschroeder • April 9, 2026

Hersh CP, Teckman JH, Strnad P, Hakim A, Carroll TP, Hall IP, Ghosh AJ, Barjaktarevic I, McElvaney NG, Kaserman JE, Lomas DA, Strange C, Drummond MB, Rennard S, Hanna KE, Clark VC, Goldklang MP, Iverson P, Wilson AA. Z variant heterozygosity in alpha-1 antitrypsin deficiency: disease risk and treatment implications. Orphanet J Rare Dis. 2026 Apr 8;21(1):136. doi: 10.1186/s13023-026-04283-9. PMID: 41952152.

Tags: alpha-1 antitrypsin, alpha-1 antitrypsin deficiency, Augmentation therapy, Carrier state, chronic liver disease, COPD, Heterozygote, Publications, Pulmonary, Critical Care & Sleep Medicine, rare disease

Related Posts

Association of Eicosanoids and Eicosanoid-Related Metabolites With Obesity and Cardiometabolic Traits

Chitsazan M, Parekh JK, Grundmann AL, Lau ES, Alotaibi M, Yu B, Rebholz CM, Selvin E, Allen NB, Allison MA, Jain M, Cheng S, Ho[...]

Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival

Podany EL, Foffano L, Gerratana L, Medford AJ, Heater NK, Nicolò E, Tapiavala S, Pontolillo L, Putur A, Jaber DA, Clifton K, Katakam N, Addison[...]

Epigenetic Clocks of Biological Aging and Cognitively Healthy Longevity: The Women’s Health Initiative Memory Study

LaCroix AZ, Zhang B, Nguyen S, Resnick SM, Ferrucci L, Horvath S, Lu AT, Espeland MA, Rapp SR, Beckman K, Nievergelt C, Maihofer AX, McEvoy[...]